HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Mehmet C. Oz David J. Pinsky Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kayano, K. Articles by Pinsky, D. J. Search for Related Content PubMed PubMed Citation Articles by Kayano, K. Articles by Pinsky, D. J.

J Thorac Cardiovasc Surg 1999;118:135-144
© 1999 Mosby, Inc.

CARDIOTHORACIC TRANSPLANTATION

SUPERIOR PROTECTION IN ORTHOTOPIC RAT LUNG TRANSPLANTATION WITH CYCLIC ADENOSINE MONOPHOSPHATE AND NITROGLYCERIN–CONTAINING PRESERVATION SOLUTION

From the College of Physicians and Surgeons of Columbia University, New York.

Supported in part by the United States Public Health Service (grants RO1 HL55397 and RO1 HL59488). Dr Pinsky is a Clinician-Scientist of the American Heart Association, Dallas, Tex.

Presented in part at the Seventieth Scientific Sessions of the American Heart Association, Orlando, Florida, November 9-12, 1997.

Address for reprints: David J. Pinsky, MD, Columbia University, College of Physicians and Surgeons, PH 10 Stem, 630 W, 168th St, New York, NY 10032. J Thorac Cardiovasc Surg 1999;118:135-44

Background: Primary lung graft failure is common, and current lung preservation strategies are suboptimal. Because the decline in lung levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate during preservation could enhance adhesiveness of endothelial cells for leukocytes as well as increase vascular permeability and vasoconstriction, we hypothesized that buttressing these levels by means of a preservation solution would significantly improve lung preservation.
Methods: An orthotopic rat left lung transplantation model was used. Lungs were harvested from male Lewis rats and preserved for 6 hours at 4°C with (1) Euro-Collins solution (n = 8); (2) University of Wisconsin solution (n = 8); (3) low-potassium dextran glucose solution (n = 8); (4) Columbia University solution (n = 8), which contains a cyclic adenosine monophosphate analog (dibutyryl cyclic adenosine monophosphate) and a nitric oxide donor (nitroglycerin) to buttress cyclic guanosine monophosphate levels; or (5) Columbia University solution without cyclic adenosine monophosphate or nitroglycerin (n = 8). PaO2, pulmonary vascular resistance, and recipient survival were evaluated 30 minutes after left lung transplantation and removal of the nontransplanted right lung from the pulmonary circulation.
Results: Among all groups studied, grafts stored with Columbia University solution demonstrated the highest Pa O2 (355 ± 25 mm Hg for Columbia University solution versus 95 ± 22 mm Hg for Euro-Collins solution, P < .01, 172 ± 55 mm Hg for University of Wisconsin solution, P < .05, 76 ± 15 mm Hg for low-potassium dextran glucose solution, P < .01, and 82 ± 25 mm Hg for Columbia University solution without cyclic adenosine monophosphate or nitroglycerin, P < .01) and the lowest pulmonary vascular resistances (1 ± 0.2 mm Hg ^· mL^{–1 ·} min^–1 for Columbia University solution versus 12 ± 4 mm Hg ^· mL^{–1 ·} min^–1 for Euro-Collins solution, P < .01, 9 ± 2 mm Hg ^· mL^{–1 ·} min^–1 for University of Wisconsin solution, 14 ± 6 mm Hg ^· mL^{–1 ·} min^–1 for low-potassium dextran glucose solution, P < .01, and 8 ± 2 mm Hg ^· mL^{–1 ·} min^–1 for Columbia University solution without cyclic adenosine monophosphate and nitroglycerin). These functional and hemodynamic improvements provided by Columbia University solution were accompanied by decreased graft leukostasis and decreased recipient tumor necrosis factor and interleukin 1 levels compared with the other groups. In toto, these improvements translated into superior survival among recipients of Columbia University solution–preserved grafts (100% for Columbia University solution, 37% for Euro-Collins solution, P < .01, 50% for University of Wisconsin solution, P < .05, 50% for low-potassium dextran glucose solution, P < .05, and 13% for Columbia University solution without cyclic adenosine monophosphate and nitroglycerin, P < .01).
Conclusion: Nitroglycerin and cyclic adenosine monophosphate confer beneficial vascular effects that make Columbia University solution a superior lung preservation solution in a stringent rat lung transplantation model.

This article has been cited by other articles:

				T. Sakaguchi, T. Asai, D. Belov, M. Okada, D. J. Pinsky, A. M. Schmidt, and Y. Naka Influence of ischemic injury on vein graft remodeling: Role of cyclic adenosine monophosphate second messenger pathway in enhanced vein graft preservation J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 129 - 137. [Abstract] [Full Text] [PDF]

				M. de Perrot, M. Liu, T. K. Waddell, and S. Keshavjee Ischemia-Reperfusion-induced Lung Injury Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 490 - 511. [Abstract] [Full Text] [PDF]

				M. R. Karamsetty and J. R. Klinger NO: More Than Just a Vasodilator in Lung Transplantation Am. J. Respir. Cell Mol. Biol., January 1, 2002; 26(1): 1 - 5. [Full Text] [PDF]

				D. J. Pinsky and Y. Naka Ann. Thorac. Surg., March 1, 2000; 69(3): 891 - 892. [Full Text] [PDF]

				K. Kayano, K. Toda, Y. Naka, and D. J. Pinsky Identification of Optimal Conditions for Lung Graft Storage With Euro-Collins Solution by Use of a Rat Orthotopic Lung Transplant Model Circulation, November 9, 1999; 100(90002): II-257 - 261. [Abstract] [Full Text] [PDF]